Ceramide Signaling

Ceramide Generation 127 Ceramide Targets 129 Ceramide Function 129 Therapeutic Implications 130 Concluding Remarks 130 14. Ceramide Glycosylation and Chemotherapy Resistance 133 Myles C. Cabot 15. Ceramide in Serum Lipoproteins: Function and Regulation of Metabolism 141 Mariana N. Nikolova-Karakashian Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141 Int roduction 141 Ceramide is a Component ofSerum Lipoproteins 142 Secretion of Ceramide in the Form ofVLOL by the Liver 142 Generation of Ceramide in LOL Particles 143 Biological Consequences of Elevation of Ceramide Concentrations in LDL 145 Conclusions and Future Directions 147 16. T herapeutic Implications of Ceramide-Regulated Signaling Cascades 149 Mark Kester, fongK Yun, Tom Stover andLakshman Sandirasegarane Abstract 149 The Bench-Ceramides and Signaling Cascades 149 The Bedside-Ceramides and Cardiovascular Disease 150 The Bedside-Ceramides and Cancer 153 The Bedside-Other Potential Applications for Ceramide-Based Therapeutics 155 Conclusions-Back to the Bench 155 Index 161 EDITOR ====================;-t Anthony H. Futerman, PhD Department of Biological Chemistry Weizmann Institute of Science Rehovot, Israel email: tony. futerman@Weizmann. ac. iI Chapter 11 I===========CONTRIBUTORS==========~ JeremyC. Allegood Myles C. Cabot Schoolof Biology John Wayne Cancer Institute Petit Institute for Bioengineering SantaMonica, California, U. S. A. and Biosciences email: cabot@jwci. org GeorgiaInstitute of Technology Chapter 14 Atlanta, Georgia, U. S. A. Chapter 1 Charles E. Chalfant Department of Biochemistry Lindsay Andras and Molecular Biology Schoolof Biology Medical University of South Carolina Petit Institute for Bioengineering Charleston, South Carolina, U. S. A. and Biosciences email: chalfant@musc. edu Georgia Institute of Technology Chapter 6 Atlanta, Georgia, U. S. A.